Evaluation of Abuse Deterrent Formulations of Oxycodone Products: Real-World Data from an Enriched Population of Substance Users Assessed with the Addiction Severity Index-Multimedia Version (ASI-MV®)

Opioid medications can provide valuable patient benefits with risks best mitigated by using formulations associated with lower likelihood of NMU, particularly via higher-risk non-oral ROAs. These study findings suggest that XTAMPZA ER has a lower risk of NMU via non-oral ROA compared to other oxycodone ER and oxycodone IR products in an enriched population of substance users.